Industry Research Reports

Home > Reports > Medical Devices & Consumables > ADAM23 Polyclonal Antibody- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

ADAM23 Polyclonal Antibody- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Industry: Medical Devices & Consumables

Published Date: 2026-01-19

Pages: 148 Pages

Report ld: 5721793

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global market for ADAM23 Polyclonal Antibody was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.

The potential shifts in the 2025 U.S. tariff framework pose substantial volatility risks to global markets. This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on ADAM23 Polyclonal Antibody cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

ADAM23 is a non-catalytic metalloprotein protein that is highly expressed in the brain, especially in the amygdala, caudate nucleus, hypothalamus, thalamus, cerebral cortex and occipital bone, and weakly expressed in the heart. ADAM23 may play a role in the interaction between cells and cell matrix. ADAM23 polyclonal antibody refers to a mixture of multiple antibodies that are isolated from the serum of immunized animals after immunizing animals with antigens containing multiple antigenic determinants of ADAM23 protein, and can specifically recognize and bind to multiple different antigenic epitopes on ADAM23 protein.

As an important tool in life science research, ADAM23 polyclonal antibody has a wide range of applications in biomedical research, drug development, clinical diagnosis and other fields. Its ability to specifically bind to ADAM23 antigen makes it an important tool for studying the function, expression regulation and related disease mechanisms of ADAM23 protein. With the continuous deepening of life science research and the rapid development of the biopharmaceutical industry, the demand for high-quality and highly specific ADAM23 polyclonal antibodies continues to grow. This growth trend has prompted relevant suppliers to increase their R&D investment and improve product quality and service levels. In summary, the ADAM23 polyclonal antibody market has broad development prospects and huge market potential.

This report provides a comprehensive view of the global market for ADAM23 Polyclonal Antibody, covering total sales volume, sales revenue, pricing, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.

The ADAM23 Polyclonal Antibody market size, estimations, and forecasts are presented in terms of sales volume (mg) and revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding ADAM23 Polyclonal Antibody.

MARKET SEGMENTATION

By Company

Abcam
Santa
ABGENT
Novus Biologicals
R&D Systems
BioLegend
Thermo Fisher Scientific
BD Biosciences
Merck Millipore
Proteintech
Beijing Biolab Technology
Annolen (Beijing) Biotechnology
Puxi (Shanghai) Biotechnology
Wuhan Biotech
Beijing Biotech
Boersen Biotechnology Shanghai
Shanghai Yuanqi Biotechnology
Merck Life Sciences
Shanghai Bohu Biotechnology

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Rabbit Antibody
Other

Segment by Application

Pharmaceutical Industry
Biomedical research
Other

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the scope of the report and the global market size (value, volume, and price). It also summarizes market dynamics and Recent Developments; identifies key drivers and restraints; outlines challenges and risks for manufacturers; reviews relevant industry policies and U.S. tariff implications.

Chapter 2: Provides a detailed analysis of the ADAM23 Polyclonal Antibody manufacturers' competitive landscape—including pricing, sales and revenue shares, Recent Developments plans, and mergers and acquisitions (M&A).

Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 5: Presents ADAM23 Polyclonal Antibody sales and revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.

Chapter 6: Presents ADAM23 Polyclonal Antibody sales and revenue at the country level. It provides segmented data by Type and by Application for each country/region.

Chapter 7: Profiles key players, detailing the main companies' product sales, revenue, pricing, gross margin, product portfolios, Recent Developments, etc.

Chapter 8: Analyzes the industry value chain, including upstream suppliers and downstream applications/customers.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 ADAM23 Polyclonal Antibody Product Introduction

1.2 Global ADAM23 Polyclonal Antibody Market Size Forecast

1.2.1 Global ADAM23 Polyclonal Antibody Sales Value (2021–2032)

1.2.2 Global ADAM23 Polyclonal Antibody Sales Volume (2021–2032)

1.2.3 Global ADAM23 Polyclonal Antibody Sales Price (2021–2032)

1.3 ADAM23 Polyclonal Antibody Market Trends & Drivers

1.3.1 ADAM23 Polyclonal Antibody Industry Trends

1.3.2 ADAM23 Polyclonal Antibody Market Drivers & Opportunities

1.3.3 ADAM23 Polyclonal Antibody Market Challenges

1.3.4 ADAM23 Polyclonal Antibody Market Restraints

1.3.5 Impact of U.S. Tariffs

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global ADAM23 Polyclonal Antibody Players Revenue Ranking (2025)

2.2 Global ADAM23 Polyclonal Antibody Revenue by Company (2021–2026)

2.3 Global ADAM23 Polyclonal Antibody Sales Volume Ranking of Players (2025)

2.4 Global ADAM23 Polyclonal Antibody Sales Volume by Company (2021–2026)

2.5 Global ADAM23 Polyclonal Antibody Average Price by Company (2021–2026)

2.6 Key Manufacturers ADAM23 Polyclonal Antibody Manufacturing Base and Headquarters

2.7 Key Manufacturers ADAM23 Polyclonal Antibody Product Offerings

2.8 Key Manufacturers Start of Mass Production of ADAM23 Polyclonal Antibody

2.9 ADAM23 Polyclonal Antibody Market Competitive Analysis

2.9.1 ADAM23 Polyclonal Antibody Market Concentration Rate (2021–2026)

2.9.2 Global 5 and 10 Largest Manufacturers by ADAM23 Polyclonal Antibody Revenue in 2025

2.9.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on ADAM23 Polyclonal Antibody revenue, 2025

2.10 Mergers & Acquisitions and Expansion

3 Segmentation ADAM23 Polyclonal Antibody Market Classification

3.1 Introduction by Type

3.1.1 Rabbit Antibody

3.1.2 Other

3.1.3 Global ADAM23 Polyclonal Antibody Sales Value by Type

3.1.3.1 Global ADAM23 Polyclonal Antibody Sales Value by Type (2021 vs 2025 vs 2032)

3.1.3.2 Global ADAM23 Polyclonal Antibody Sales Value, by Type (2021–2032)

3.1.3.3 Global ADAM23 Polyclonal Antibody Sales Value, by Type (%), 2021–2032

3.1.4 Global ADAM23 Polyclonal Antibody Sales Volume by Type

3.1.4.1 Global ADAM23 Polyclonal Antibody Sales Volume by Type (2021 vs 2025 vs 2032)

3.1.4.2 Global ADAM23 Polyclonal Antibody Sales Volume, by Type (2021–2032)

3.1.4.3 Global ADAM23 Polyclonal Antibody Sales Volume, by Type (%), 2021–2032

3.1.5 Global ADAM23 Polyclonal Antibody Average Price by Type (2021–2032)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Pharmaceutical Industry

4.1.2 Biomedical research

4.1.3 Other

4.2 Global ADAM23 Polyclonal Antibody Sales Value by Application

4.2.1 Global ADAM23 Polyclonal Antibody Sales Value by Application (2021 vs 2025 vs 2032)

4.2.2 Global ADAM23 Polyclonal Antibody Sales Value, by Application (2021–2032)

4.2.3 Global ADAM23 Polyclonal Antibody Sales Value, by Application (%), 2021–2032

4.3 Global ADAM23 Polyclonal Antibody Sales Volume by Application

4.3.1 Global ADAM23 Polyclonal Antibody Sales Volume by Application (2021 vs 2025 vs 2032)

4.3.2 Global ADAM23 Polyclonal Antibody Sales Volume, by Application (2021–2032)

4.3.3 Global ADAM23 Polyclonal Antibody Sales Volume, by Application (%), 2021–2032

4.4 Global ADAM23 Polyclonal Antibody Average Price by Application (2021–2032)

5 Segmentation by Region

5.1 Global ADAM23 Polyclonal Antibody Sales Value by Region

5.1.1 Global ADAM23 Polyclonal Antibody Sales Value by Region: 2021 vs 2025 vs 2032

5.1.2 Global ADAM23 Polyclonal Antibody Sales Value by Region (2021–2026)

5.1.3 Global ADAM23 Polyclonal Antibody Sales Value by Region (2027–2032)

5.1.4 Global ADAM23 Polyclonal Antibody Sales Value by Region (%), 2021–2032

5.2 Global ADAM23 Polyclonal Antibody Sales Volume by Region

5.2.1 Global ADAM23 Polyclonal Antibody Sales Volume by Region: 2021 vs 2025 vs 2032

5.2.2 Global ADAM23 Polyclonal Antibody Sales Volume by Region (2021–2026)

5.2.3 Global ADAM23 Polyclonal Antibody Sales Volume by Region (2027–2032)

5.2.4 Global ADAM23 Polyclonal Antibody Sales Volume by Region (%), 2021–2032

5.3 Global ADAM23 Polyclonal Antibody Average Price by Region (2021–2032)

5.4 North America

5.4.1 North America ADAM23 Polyclonal Antibody Sales Value, 2021–2032

5.4.2 North America ADAM23 Polyclonal Antibody Sales Value by Country (%), 2025 vs 2032

5.5 Europe

5.5.1 Europe ADAM23 Polyclonal Antibody Sales Value, 2021–2032

5.5.2 Europe ADAM23 Polyclonal Antibody Sales Value by Country (%), 2025 vs 2032

5.6 Asia Pacific

5.6.1 Asia Pacific ADAM23 Polyclonal Antibody Sales Value, 2021–2032

5.6.2 Asia Pacific ADAM23 Polyclonal Antibody Sales Value by Region (%), 2025 vs 2032

5.7 South America

5.7.1 South America ADAM23 Polyclonal Antibody Sales Value, 2021–2032

5.7.2 South America ADAM23 Polyclonal Antibody Sales Value by Country (%), 2025 vs 2032

5.8 Middle East & Africa

5.8.1 Middle East & Africa ADAM23 Polyclonal Antibody Sales Value, 2021–2032

5.8.2 Middle East & Africa ADAM23 Polyclonal Antibody Sales Value by Country (%), 2025 vs 2032

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions ADAM23 Polyclonal Antibody Sales Value Growth Trends, 2021 vs 2025 vs 2032

6.2 Key Countries/Regions ADAM23 Polyclonal Antibody Sales Value and Sales Volume

6.2.1 Key Countries/Regions ADAM23 Polyclonal Antibody Sales Value, 2021–2032

6.2.2 Key Countries/Regions ADAM23 Polyclonal Antibody Sales Volume, 2021–2032

6.3 United States

6.3.1 United States ADAM23 Polyclonal Antibody Sales Value, 2021–2032

6.3.2 United States ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

6.3.3 United States ADAM23 Polyclonal Antibody Sales Value by Application, 2025 vs 2032

6.4 Europe

6.4.1 Europe ADAM23 Polyclonal Antibody Sales Value, 2021–2032

6.4.2 Europe ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

6.4.3 Europe ADAM23 Polyclonal Antibody Sales Value by Application, 2025 vs 2032

6.5 China

6.5.1 China ADAM23 Polyclonal Antibody Sales Value, 2021–2032

6.5.2 China ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

6.5.3 China ADAM23 Polyclonal Antibody Sales Value by Application, 2025 vs 2032

6.6 Japan

6.6.1 Japan ADAM23 Polyclonal Antibody Sales Value, 2021–2032

6.6.2 Japan ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

6.6.3 Japan ADAM23 Polyclonal Antibody Sales Value by Application, 2025 vs 2032

6.7 South Korea

6.7.1 South Korea ADAM23 Polyclonal Antibody Sales Value, 2021–2032

6.7.2 South Korea ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

6.7.3 South Korea ADAM23 Polyclonal Antibody Sales Value by Application, 2025 vs 2032

6.8 Southeast Asia

6.8.1 Southeast Asia ADAM23 Polyclonal Antibody Sales Value, 2021–2032

6.8.2 Southeast Asia ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

6.8.3 Southeast Asia ADAM23 Polyclonal Antibody Sales Value by Application, 2025 vs 2032

6.9 India

6.9.1 India ADAM23 Polyclonal Antibody Sales Value, 2021–2032

6.9.2 India ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

6.9.3 India ADAM23 Polyclonal Antibody Sales Value by Application, 2025 vs 2032

7 Company Profiles

7.1 Abcam

7.1.1 Abcam Company Information

7.1.2 Abcam Introduction and Business Overview

7.1.3 Abcam ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.1.4 Abcam ADAM23 Polyclonal Antibody Product Offerings

7.1.5 Abcam Recent Developments

7.2 Santa

7.2.1 Santa Company Information

7.2.2 Santa Introduction and Business Overview

7.2.3 Santa ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.2.4 Santa ADAM23 Polyclonal Antibody Product Offerings

7.2.5 Santa Recent Developments

7.3 ABGENT

7.3.1 ABGENT Company Information

7.3.2 ABGENT Introduction and Business Overview

7.3.3 ABGENT ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.3.4 ABGENT ADAM23 Polyclonal Antibody Product Offerings

7.3.5 ABGENT Recent Developments

7.4 Novus Biologicals

7.4.1 Novus Biologicals Company Information

7.4.2 Novus Biologicals Introduction and Business Overview

7.4.3 Novus Biologicals ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.4.4 Novus Biologicals ADAM23 Polyclonal Antibody Product Offerings

7.4.5 Novus Biologicals Recent Developments

7.5 R&D Systems

7.5.1 R&D Systems Company Information

7.5.2 R&D Systems Introduction and Business Overview

7.5.3 R&D Systems ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.5.4 R&D Systems ADAM23 Polyclonal Antibody Product Offerings

7.5.5 R&D Systems Recent Developments

7.6 BioLegend

7.6.1 BioLegend Company Information

7.6.2 BioLegend Introduction and Business Overview

7.6.3 BioLegend ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.6.4 BioLegend ADAM23 Polyclonal Antibody Product Offerings

7.6.5 BioLegend Recent Developments

7.7 Thermo Fisher Scientific

7.7.1 Thermo Fisher Scientific Company Information

7.7.2 Thermo Fisher Scientific Introduction and Business Overview

7.7.3 Thermo Fisher Scientific ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.7.4 Thermo Fisher Scientific ADAM23 Polyclonal Antibody Product Offerings

7.7.5 Thermo Fisher Scientific Recent Developments

7.8 BD Biosciences

7.8.1 BD Biosciences Company Information

7.8.2 BD Biosciences Introduction and Business Overview

7.8.3 BD Biosciences ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.8.4 BD Biosciences ADAM23 Polyclonal Antibody Product Offerings

7.8.5 BD Biosciences Recent Developments

7.9 Merck Millipore

7.9.1 Merck Millipore Company Information

7.9.2 Merck Millipore Introduction and Business Overview

7.9.3 Merck Millipore ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.9.4 Merck Millipore ADAM23 Polyclonal Antibody Product Offerings

7.9.5 Merck Millipore Recent Developments

7.10 Proteintech

7.10.1 Proteintech Company Information

7.10.2 Proteintech Introduction and Business Overview

7.10.3 Proteintech ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.10.4 Proteintech ADAM23 Polyclonal Antibody Product Offerings

7.10.5 Proteintech Recent Developments

7.11 Beijing Biolab Technology

7.11.1 Beijing Biolab Technology Company Information

7.11.2 Beijing Biolab Technology Introduction and Business Overview

7.11.3 Beijing Biolab Technology ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.11.4 Beijing Biolab Technology ADAM23 Polyclonal Antibody Product Offerings

7.11.5 Beijing Biolab Technology Recent Developments

7.12 Annolen (Beijing) Biotechnology

7.12.1 Annolen (Beijing) Biotechnology Company Information

7.12.2 Annolen (Beijing) Biotechnology Introduction and Business Overview

7.12.3 Annolen (Beijing) Biotechnology ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.12.4 Annolen (Beijing) Biotechnology ADAM23 Polyclonal Antibody Product Offerings

7.12.5 Annolen (Beijing) Biotechnology Recent Developments

7.13 Puxi (Shanghai) Biotechnology

7.13.1 Puxi (Shanghai) Biotechnology Company Information

7.13.2 Puxi (Shanghai) Biotechnology Introduction and Business Overview

7.13.3 Puxi (Shanghai) Biotechnology ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.13.4 Puxi (Shanghai) Biotechnology ADAM23 Polyclonal Antibody Product Offerings

7.13.5 Puxi (Shanghai) Biotechnology Recent Developments

7.14 Wuhan Biotech

7.14.1 Wuhan Biotech Company Information

7.14.2 Wuhan Biotech Introduction and Business Overview

7.14.3 Wuhan Biotech ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.14.4 Wuhan Biotech ADAM23 Polyclonal Antibody Product Offerings

7.14.5 Wuhan Biotech Recent Developments

7.15 Beijing Biotech

7.15.1 Beijing Biotech Company Information

7.15.2 Beijing Biotech Introduction and Business Overview

7.15.3 Beijing Biotech ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.15.4 Beijing Biotech ADAM23 Polyclonal Antibody Product Offerings

7.15.5 Beijing Biotech Recent Developments

7.16 Boersen Biotechnology Shanghai

7.16.1 Boersen Biotechnology Shanghai Company Information

7.16.2 Boersen Biotechnology Shanghai Introduction and Business Overview

7.16.3 Boersen Biotechnology Shanghai ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.16.4 Boersen Biotechnology Shanghai ADAM23 Polyclonal Antibody Product Offerings

7.16.5 Boersen Biotechnology Shanghai Recent Developments

7.17 Shanghai Yuanqi Biotechnology

7.17.1 Shanghai Yuanqi Biotechnology Company Information

7.17.2 Shanghai Yuanqi Biotechnology Introduction and Business Overview

7.17.3 Shanghai Yuanqi Biotechnology ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.17.4 Shanghai Yuanqi Biotechnology ADAM23 Polyclonal Antibody Product Offerings

7.17.5 Shanghai Yuanqi Biotechnology Recent Developments

7.18 Merck Life Sciences

7.18.1 Merck Life Sciences Company Information

7.18.2 Merck Life Sciences Introduction and Business Overview

7.18.3 Merck Life Sciences ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.18.4 Merck Life Sciences ADAM23 Polyclonal Antibody Product Offerings

7.18.5 Merck Life Sciences Recent Developments

7.19 Shanghai Bohu Biotechnology

7.19.1 Shanghai Bohu Biotechnology Company Information

7.19.2 Shanghai Bohu Biotechnology Introduction and Business Overview

7.19.3 Shanghai Bohu Biotechnology ADAM23 Polyclonal Antibody Sales, Revenue, Price and Gross Margin (2021–2026)

7.19.4 Shanghai Bohu Biotechnology ADAM23 Polyclonal Antibody Product Offerings

7.19.5 Shanghai Bohu Biotechnology Recent Developments

8 Industry Chain Analysis

8.1 ADAM23 Polyclonal Antibody Industrial Chain

8.2 ADAM23 Polyclonal Antibody Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Key Suppliers of Raw Materials

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customer Analysis)

8.5 Sales Model and Sales Channelss

8.5.1 ADAM23 Polyclonal Antibody Sales Model

8.5.2 Sales Channels

8.5.3 ADAM23 Polyclonal Antibody Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. ADAM23 Polyclonal Antibody Market Trends

Table 2. ADAM23 Polyclonal Antibody Market Drivers & Opportunities

Table 3. ADAM23 Polyclonal Antibody Market Challenges

Table 4. ADAM23 Polyclonal Antibody Market Restraints

Table 5. Global ADAM23 Polyclonal Antibody Revenue by Company (US$ Million), 2021–2026

Table 6. Global ADAM23 Polyclonal Antibody Revenue Market Share by Company (2021–2026)

Table 7. Global ADAM23 Polyclonal Antibody Sales Volume by Company (mg), 2021–2026

Table 8. Global ADAM23 Polyclonal Antibody Sales Volume Market Share by Company (2021–2026)

Table 9. Global Market ADAM23 Polyclonal Antibody Price by Company (US$/μg), 2021–2026

Table 10. Key Manufacturers ADAM23 Polyclonal Antibody Manufacturing Base and Headquarters

Table 11. Key Manufacturers ADAM23 Polyclonal Antibody Product Type

Table 12. Key Manufacturers Start of Mass Production of ADAM23 Polyclonal Antibody

Table 13. Global ADAM23 Polyclonal Antibody Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Tier (Tier 1, Tier 2, Tier 3), based on ADAM23 Polyclonal Antibody revenue, 2025

Table 15. Mergers & Acquisitions and Expansion Plans

Table 16. Global ADAM23 Polyclonal Antibody Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)

Table 17. Global ADAM23 Polyclonal Antibody Sales Value by Type (US$ Million), 2021–2026

Table 18. Global ADAM23 Polyclonal Antibody Sales Value by Type (US$ Million), 2027–2032

Table 19. Global ADAM23 Polyclonal Antibody Sales Market Share in Value by Type (2021–2026)

Table 20. Global ADAM23 Polyclonal Antibody Sales Market Share in Value by Type (2027–2032)

Table 21. Global ADAM23 Polyclonal Antibody Sales Volume by Type: 2021 vs 2025 vs 2032 (mg)

Table 22. Global ADAM23 Polyclonal Antibody Sales Volume by Type (mg), 2021–2026

Table 23. Global ADAM23 Polyclonal Antibody Sales Volume by Type (mg), 2027–2032

Table 24. Global ADAM23 Polyclonal Antibody Sales Market Share in Volume by Type (2021–2026)

Table 25. Global ADAM23 Polyclonal Antibody Sales Market Share in Volume by Type (2027–2032)

Table 26. Global ADAM23 Polyclonal Antibody Price by Type (US$/μg), 2021–2026

Table 27. Global ADAM23 Polyclonal Antibody Price by Type (US$/μg), 2027–2032

Table 28. Global ADAM23 Polyclonal Antibody Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)

Table 29. Global ADAM23 Polyclonal Antibody Sales Value by Application (US$ Million), 2021–2026

Table 30. Global ADAM23 Polyclonal Antibody Sales Value by Application (US$ Million), 2027–2032

Table 31. Global ADAM23 Polyclonal Antibody Sales Market Share in Value by Application (2021–2026)

Table 32. Global ADAM23 Polyclonal Antibody Sales Market Share in Value by Application (2027–2032)

Table 33. Global ADAM23 Polyclonal Antibody Sales Volume by Application: 2021 vs 2025 vs 2032 (mg)

Table 34. Global ADAM23 Polyclonal Antibody Sales Volume by Application (mg), 2021–2026

Table 35. Global ADAM23 Polyclonal Antibody Sales Volume by Application (mg), 2027–2032

Table 36. Global ADAM23 Polyclonal Antibody Sales Market Share in Volume by Application (2021–2026)

Table 37. Global ADAM23 Polyclonal Antibody Sales Market Share in Volume by Application (2027–2032)

Table 38. Global ADAM23 Polyclonal Antibody Price by Application (US$/μg), 2021–2026

Table 39. Global ADAM23 Polyclonal Antibody Price by Application (US$/μg), 2027–2032

Table 40. Global ADAM23 Polyclonal Antibody Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032

Table 41. Global ADAM23 Polyclonal Antibody Sales Value by Region (US$ Million), 2021–2026

Table 42. Global ADAM23 Polyclonal Antibody Sales Value by Region (US$ Million), 2027–2032

Table 43. Global ADAM23 Polyclonal Antibody Sales Value by Region (%), 2021–2026

Table 44. Global ADAM23 Polyclonal Antibody Sales Value by Region (%), 2027–2032

Table 45. Global ADAM23 Polyclonal Antibody Sales Volume by Region (mg): 2021 vs 2025 vs 2032

Table 46. Global ADAM23 Polyclonal Antibody Sales Volume by Region (mg), 2021–2026

Table 47. Global ADAM23 Polyclonal Antibody Sales Volume by Region (mg), 2027–2032

Table 48. Global ADAM23 Polyclonal Antibody Sales Volume by Region (%), 2021–2026

Table 49. Global ADAM23 Polyclonal Antibody Sales Volume by Region (%), 2027–2032

Table 50. Global ADAM23 Polyclonal Antibody Average Price by Region (US$/μg), 2021–2026

Table 51. Global ADAM23 Polyclonal Antibody Average Price by Region (US$/μg), 2027–2032

Table 52. Key Countries/Regions ADAM23 Polyclonal Antibody Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032

Table 53. Key Countries/Regions ADAM23 Polyclonal Antibody Sales Value, (US$ Million), 2021–2026

Table 54. Key Countries/Regions ADAM23 Polyclonal Antibody Sales Value, (US$ Million), 2027–2032

Table 55. Key Countries/Regions ADAM23 Polyclonal Antibody Sales Volume, (mg), 2021–2026

Table 56. Key Countries/Regions ADAM23 Polyclonal Antibody Sales Volume, (mg), 2027–2032

Table 57. Abcam Company Information

Table 58. Abcam Introduction and Business Overview

Table 59. Abcam ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 60. Abcam ADAM23 Polyclonal Antibody Product Offerings

Table 61. Abcam Recent Developments

Table 62. Santa Company Information

Table 63. Santa Introduction and Business Overview

Table 64. Santa ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 65. Santa ADAM23 Polyclonal Antibody Product Offerings

Table 66. Santa Recent Developments

Table 67. ABGENT Company Information

Table 68. ABGENT Introduction and Business Overview

Table 69. ABGENT ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 70. ABGENT ADAM23 Polyclonal Antibody Product Offerings

Table 71. ABGENT Recent Developments

Table 72. Novus Biologicals Company Information

Table 73. Novus Biologicals Introduction and Business Overview

Table 74. Novus Biologicals ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 75. Novus Biologicals ADAM23 Polyclonal Antibody Product Offerings

Table 76. Novus Biologicals Recent Developments

Table 77. R&D Systems Company Information

Table 78. R&D Systems Introduction and Business Overview

Table 79. R&D Systems ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 80. R&D Systems ADAM23 Polyclonal Antibody Product Offerings

Table 81. R&D Systems Recent Developments

Table 82. BioLegend Company Information

Table 83. BioLegend Introduction and Business Overview

Table 84. BioLegend ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 85. BioLegend ADAM23 Polyclonal Antibody Product Offerings

Table 86. BioLegend Recent Developments

Table 87. Thermo Fisher Scientific Company Information

Table 88. Thermo Fisher Scientific Introduction and Business Overview

Table 89. Thermo Fisher Scientific ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 90. Thermo Fisher Scientific ADAM23 Polyclonal Antibody Product Offerings

Table 91. Thermo Fisher Scientific Recent Developments

Table 92. BD Biosciences Company Information

Table 93. BD Biosciences Introduction and Business Overview

Table 94. BD Biosciences ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 95. BD Biosciences ADAM23 Polyclonal Antibody Product Offerings

Table 96. BD Biosciences Recent Developments

Table 97. Merck Millipore Company Information

Table 98. Merck Millipore Introduction and Business Overview

Table 99. Merck Millipore ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 100. Merck Millipore ADAM23 Polyclonal Antibody Product Offerings

Table 101. Merck Millipore Recent Developments

Table 102. Proteintech Company Information

Table 103. Proteintech Introduction and Business Overview

Table 104. Proteintech ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 105. Proteintech ADAM23 Polyclonal Antibody Product Offerings

Table 106. Proteintech Recent Developments

Table 107. Beijing Biolab Technology Company Information

Table 108. Beijing Biolab Technology Introduction and Business Overview

Table 109. Beijing Biolab Technology ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 110. Beijing Biolab Technology ADAM23 Polyclonal Antibody Product Offerings

Table 111. Beijing Biolab Technology Recent Developments

Table 112. Annolen (Beijing) Biotechnology Company Information

Table 113. Annolen (Beijing) Biotechnology Introduction and Business Overview

Table 114. Annolen (Beijing) Biotechnology ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 115. Annolen (Beijing) Biotechnology ADAM23 Polyclonal Antibody Product Offerings

Table 116. Annolen (Beijing) Biotechnology Recent Developments

Table 117. Puxi (Shanghai) Biotechnology Company Information

Table 118. Puxi (Shanghai) Biotechnology Introduction and Business Overview

Table 119. Puxi (Shanghai) Biotechnology ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 120. Puxi (Shanghai) Biotechnology ADAM23 Polyclonal Antibody Product Offerings

Table 121. Puxi (Shanghai) Biotechnology Recent Developments

Table 122. Wuhan Biotech Company Information

Table 123. Wuhan Biotech Introduction and Business Overview

Table 124. Wuhan Biotech ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 125. Wuhan Biotech ADAM23 Polyclonal Antibody Product Offerings

Table 126. Wuhan Biotech Recent Developments

Table 127. Beijing Biotech Company Information

Table 128. Beijing Biotech Introduction and Business Overview

Table 129. Beijing Biotech ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 130. Beijing Biotech ADAM23 Polyclonal Antibody Product Offerings

Table 131. Beijing Biotech Recent Developments

Table 132. Boersen Biotechnology Shanghai Company Information

Table 133. Boersen Biotechnology Shanghai Introduction and Business Overview

Table 134. Boersen Biotechnology Shanghai ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 135. Boersen Biotechnology Shanghai ADAM23 Polyclonal Antibody Product Offerings

Table 136. Boersen Biotechnology Shanghai Recent Developments

Table 137. Shanghai Yuanqi Biotechnology Company Information

Table 138. Shanghai Yuanqi Biotechnology Introduction and Business Overview

Table 139. Shanghai Yuanqi Biotechnology ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 140. Shanghai Yuanqi Biotechnology ADAM23 Polyclonal Antibody Product Offerings

Table 141. Shanghai Yuanqi Biotechnology Recent Developments

Table 142. Merck Life Sciences Company Information

Table 143. Merck Life Sciences Introduction and Business Overview

Table 144. Merck Life Sciences ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 145. Merck Life Sciences ADAM23 Polyclonal Antibody Product Offerings

Table 146. Merck Life Sciences Recent Developments

Table 147. Shanghai Bohu Biotechnology Company Information

Table 148. Shanghai Bohu Biotechnology Introduction and Business Overview

Table 149. Shanghai Bohu Biotechnology ADAM23 Polyclonal Antibody Sales (mg), Revenue (US$ Million), Price (US$/μg) and Gross Margin (2021–2026)

Table 150. Shanghai Bohu Biotechnology ADAM23 Polyclonal Antibody Product Offerings

Table 151. Shanghai Bohu Biotechnology Recent Developments

Table 152. Key Raw Materials Lists

Table 153. Key Suppliers of Raw Materials Lists

Table 154. ADAM23 Polyclonal Antibody Downstream Customers

Table 155. ADAM23 Polyclonal Antibody Distributors List

Table 156. Research Programs/Design for This Report

Table 157. Key Data Information from Secondary Sources

Table 158. Key Data Information from Primary Sources

List of Figures

Figure 1. ADAM23 Polyclonal Antibody Product Picture

Figure 2. Global ADAM23 Polyclonal Antibody Sales Value, 2021 vs 2025 vs 2032 (US$ Million)

Figure 3. Global ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 4. Global ADAM23 Polyclonal Antibody Sales Volume (mg), 2021–2032

Figure 5. Global ADAM23 Polyclonal Antibody Sales Price (US$/μg), 2021–2032

Figure 6. ADAM23 Polyclonal Antibody Report Years Considered

Figure 7. Global ADAM23 Polyclonal Antibody Players Revenue Ranking (US$ Million), 2025

Figure 8. Global ADAM23 Polyclonal Antibody Sales Volume Ranking of Players (mg), 2025

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by ADAM23 Polyclonal Antibody Revenue in 2025

Figure 10. ADAM23 Polyclonal Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 11. Rabbit Antibody Picture

Figure 12. Other Picture

Figure 13. Global ADAM23 Polyclonal Antibody Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global ADAM23 Polyclonal Antibody Sales Value Market Share by Type, 2025 & 2032

Figure 15. Global ADAM23 Polyclonal Antibody Sales Volume by Type (mg), 2021 vs 2025 vs 2032

Figure 16. Global ADAM23 Polyclonal Antibody Sales Volume Market Share by Type, 2025 & 2032

Figure 17. Global ADAM23 Polyclonal Antibody Price by Type (US$/μg), 2021–2032

Figure 18. Product Picture of Pharmaceutical Industry

Figure 19. Product Picture of Biomedical research

Figure 20. Product Picture of Other

Figure 21. Global ADAM23 Polyclonal Antibody Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032

Figure 22. Global ADAM23 Polyclonal Antibody Sales Value Market Share by Application, 2025 & 2032

Figure 23. Global ADAM23 Polyclonal Antibody Sales Volume by Application (mg), 2021 vs 2025 vs 2032

Figure 24. Global ADAM23 Polyclonal Antibody Sales Volume Market Share by Application, 2025 & 2032

Figure 25. Global ADAM23 Polyclonal Antibody Price by Application (US$/μg), 2021–2032

Figure 26. North America ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 27. North America ADAM23 Polyclonal Antibody Sales Value by Country (%), 2025 vs 2032

Figure 28. Europe ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 29. Europe ADAM23 Polyclonal Antibody Sales Value by Country (%), 2025 vs 2032

Figure 30. Asia Pacific ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 31. Asia Pacific ADAM23 Polyclonal Antibody Sales Value by Region (%), 2025 vs 2032

Figure 32. South America ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 33. South America ADAM23 Polyclonal Antibody Sales Value by Country (%), 2025 vs 2032

Figure 34. Middle East & Africa ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 35. Middle East & Africa ADAM23 Polyclonal Antibody Sales Value by Country (%), 2025 vs 2032

Figure 36. Key Countries/Regions ADAM23 Polyclonal Antibody Sales Value (%), 2021–2032

Figure 37. Key Countries/Regions ADAM23 Polyclonal Antibody Sales Volume (%), 2021–2032

Figure 38. United States ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 39. United States ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

Figure 40. United States ADAM23 Polyclonal Antibody Sales Value by Application (%), 2025 vs 2032

Figure 41. Europe ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 42. Europe ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

Figure 43. Europe ADAM23 Polyclonal Antibody Sales Value by Application (%), 2025 vs 2032

Figure 44. China ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 45. China ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

Figure 46. China ADAM23 Polyclonal Antibody Sales Value by Application (%), 2025 vs 2032

Figure 47. Japan ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 48. Japan ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

Figure 49. Japan ADAM23 Polyclonal Antibody Sales Value by Application (%), 2025 vs 2032

Figure 50. South Korea ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 51. South Korea ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

Figure 52. South Korea ADAM23 Polyclonal Antibody Sales Value by Application (%), 2025 vs 2032

Figure 53. Southeast Asia ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 54. Southeast Asia ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

Figure 55. Southeast Asia ADAM23 Polyclonal Antibody Sales Value by Application (%), 2025 vs 2032

Figure 56. India ADAM23 Polyclonal Antibody Sales Value (US$ Million), 2021–2032

Figure 57. India ADAM23 Polyclonal Antibody Sales Value by Type (%), 2025 vs 2032

Figure 58. India ADAM23 Polyclonal Antibody Sales Value by Application (%), 2025 vs 2032

Figure 59. ADAM23 Polyclonal Antibody Industrial Chain

Figure 60. ADAM23 Polyclonal Antibody Manufacturing Cost Structure

Figure 61. Channels of Distribution (Direct Sales, and Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global ADAM23 Polyclonal Antibody market? zhanKai

The top companies in the global ADAM23 Polyclonal Antibody market are Abcam、Santa、ABGENT.

Related Reports

Global ADAM23 Polyclonal Antibody Market Outlook, In‑Depth Analysis & Forecast to 2032
The global ADAM23 Polyclonal Antibody market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-03-26
Pages: 175
USD 4900.00
(Single User License)
Global ADAM23 Polyclonal Antibody Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global ADAM23 Polyclonal Antibody market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 107
USD 4250.00
(Single User License)
Global ADAM23 Polyclonal Antibody Market Research Report 2026
The global ADAM23 Polyclonal Antibody market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-14
Pages: 134
USD 2900.00
(Single User License)
Global ADAM23 Polyclonal Antibody Market Outlook, In‑Depth Analysis & Forecast to 2031
The global ADAM23 Polyclonal Antibody market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-08-05
Pages: 175
USD 4900.00
(Single User License)
Global ADAM23 Polyclonal Antibody Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global ADAM23 Polyclonal Antibody market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-08-01
Pages: 107
USD 4250.00
(Single User License)
ADAM23 Polyclonal Antibody - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for ADAM23 Polyclonal Antibody was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-03-10
Pages: 140
USD 3950.00
(Single User License)
Global ADAM23 Polyclonal Antibody Market Research Report 2025
The global market for ADAM23 Polyclonal Antibody was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-03-10
Pages: 99
USD 2900.00
(Single User License)
Global and United States ADAM23 Polyclonal Antibody Market Report & Forecast 2024-2030
ADAM23 is a non-catalytic metalloprotein protein that is highly expressed in the brain, especially in the amygdala, caudate nucleus, hypothalamus, thalamus, cerebral cortex and occipital bone, and weakly expressed in the heart. ADAM23 may play a role in the interaction between cells and cell matrix. ADAM23 polyclonal antibody refers to a mixture of multiple antibodies that are isolated from the serum of immunized animals after immunizing animals with antigens containing multiple antigenic determinants of ADAM23 protein, and can specifically recognize and bind to multiple different antigenic epitopes on ADAM23 protein.
Published Date: 2024-07-26
Pages: 148
USD 4350.00
(Single User License)
Global ADAM23 Polyclonal Antibody Market Insights, Forecast to 2030
ADAM23 is a non-catalytic metalloprotein protein that is highly expressed in the brain, especially in the amygdala, caudate nucleus, hypothalamus, thalamus, cerebral cortex and occipital bone, and weakly expressed in the heart. ADAM23 may play a role in the interaction between cells and cell matrix. ADAM23 polyclonal antibody refers to a mixture of multiple antibodies that are isolated from the serum of immunized animals after immunizing animals with antigens containing multiple antigenic determinants of ADAM23 protein, and can specifically recognize and bind to multiple different antigenic epitopes on ADAM23 protein.
Published Date: 2024-07-26
Pages: 185
USD 4900.00
(Single User License)
Global ADAM23 Polyclonal Antibody Market Research Report 2024
ADAM23 is a non-catalytic metalloprotein protein that is highly expressed in the brain, especially in the amygdala, caudate nucleus, hypothalamus, thalamus, cerebral cortex and occipital bone, and weakly expressed in the heart. ADAM23 may play a role in the interaction between cells and cell matrix. ADAM23 polyclonal antibody refers to a mixture of multiple antibodies that are isolated from the serum of immunized animals after immunizing animals with antigens containing multiple antigenic determinants of ADAM23 protein, and can specifically recognize and bind to multiple different antigenic epitopes on ADAM23 protein.
Published Date: 2024-07-26
Pages: 101
USD 2900.00
(Single User License)

Global ADAM23 Polyclonal Antibody Market Outlook, In‑Depth Analysis & Forecast to 2032
The global ADAM23 Polyclonal Antibody market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-03-26
Pages: 175
USD 4900.00 (Single User License)
Global ADAM23 Polyclonal Antibody Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global ADAM23 Polyclonal Antibody market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 107
USD 4250.00 (Single User License)
Global ADAM23 Polyclonal Antibody Market Research Report 2026
The global ADAM23 Polyclonal Antibody market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-01-14
Pages: 134
USD 2900.00 (Single User License)
Global ADAM23 Polyclonal Antibody Market Outlook, In‑Depth Analysis & Forecast to 2031
The global ADAM23 Polyclonal Antibody market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-08-05
Pages: 175
USD 4900.00 (Single User License)
Global ADAM23 Polyclonal Antibody Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global ADAM23 Polyclonal Antibody market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-08-01
Pages: 107
USD 4250.00 (Single User License)
ADAM23 Polyclonal Antibody - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for ADAM23 Polyclonal Antibody was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-03-10
Pages: 140
USD 3950.00 (Single User License)
Global ADAM23 Polyclonal Antibody Market Research Report 2025
The global market for ADAM23 Polyclonal Antibody was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-03-10
Pages: 99
USD 2900.00 (Single User License)
Global and United States ADAM23 Polyclonal Antibody Market Report & Forecast 2024-2030
ADAM23 is a non-catalytic metalloprotein protein that is highly expressed in the brain, especially in the amygdala, caudate nucleus, hypothalamus, thalamus, cerebral cortex and occipital bone, and weakly expressed in the heart. ADAM23 may play a role in the interaction between cells and cell matrix. ADAM23 polyclonal antibody refers to a mixture of multiple antibodies that are isolated from the serum of immunized animals after immunizing animals with antigens containing multiple antigenic determinants of ADAM23 protein, and can specifically recognize and bind to multiple different antigenic epitopes on ADAM23 protein.
Published: 2024-07-26
Pages: 148
USD 4350.00 (Single User License)
Global ADAM23 Polyclonal Antibody Market Insights, Forecast to 2030
ADAM23 is a non-catalytic metalloprotein protein that is highly expressed in the brain, especially in the amygdala, caudate nucleus, hypothalamus, thalamus, cerebral cortex and occipital bone, and weakly expressed in the heart. ADAM23 may play a role in the interaction between cells and cell matrix. ADAM23 polyclonal antibody refers to a mixture of multiple antibodies that are isolated from the serum of immunized animals after immunizing animals with antigens containing multiple antigenic determinants of ADAM23 protein, and can specifically recognize and bind to multiple different antigenic epitopes on ADAM23 protein.
Published: 2024-07-26
Pages: 185
USD 4900.00 (Single User License)
Global ADAM23 Polyclonal Antibody Market Research Report 2024
ADAM23 is a non-catalytic metalloprotein protein that is highly expressed in the brain, especially in the amygdala, caudate nucleus, hypothalamus, thalamus, cerebral cortex and occipital bone, and weakly expressed in the heart. ADAM23 may play a role in the interaction between cells and cell matrix. ADAM23 polyclonal antibody refers to a mixture of multiple antibodies that are isolated from the serum of immunized animals after immunizing animals with antigens containing multiple antigenic determinants of ADAM23 protein, and can specifically recognize and bind to multiple different antigenic epitopes on ADAM23 protein.
Published: 2024-07-26
Pages: 101
USD 2900.00 (Single User License)